Application of NAAA in prevention or treatment of stroke or post-stroke anxiety

By developing NAAA inhibitors and knockout technology, the treatment problems of stroke and post-stroke anxiety were solved, significantly reducing the volume and anxiety manifestations of post-stroke infarction, providing new therapeutic targets and drug development directions.

CN119015425AInactive Publication Date: 2024-11-26UNIV OF SCI & TECH OF CHINA +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411265846.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent or treat stroke and poststroke anxiety, especially due to the unclear role of N-acylethanolamine acid hydrolase (NAAA) in this process, resulting in a lack of effective therapeutic targets.

Method used

Drugs and reagents for preventing or treating stroke and poststroke anxiety, including liquid, solid, semi-solid and Pharmaceutical preparations in gas dosage forms.

Benefits of technology

Experimental results show that NAAA knockout or inhibitors can significantly reduce the volume of infarction after stroke and reduce the behavioral manifestations of poststroke anxiety, providing important prevention and treatment strategies, and significantly prevent and treat stroke and poststroke anxiety. significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015425A_ABST
    Figure CN119015425A_ABST
Patent Text Reader

Abstract

The invention proposes that NAAA is a drug target for treating cerebral apoplexy and post-stroke anxiety related diseases for the first time. Experiments show that in mice with stroke (PTS) and post-stroke anxiety (PSA), the expression quantity of NAAA in cerebral cortex is obviously increased. After cerebral apoplexy, the infarct volume of the NAAA knockout mouse PTS in 5 days is obviously reduced, and anxiety-like behaviors of the NAAA knockout mouse PSA14 days, 16 days and 18 days in bead burying, open field and elevated cross maze experiments are obviously reduced. The NAAA inhibitor is continuously injected in the intraperitoneal cavity for 3 days after the stroke, so that the recovery of the infarct area of the stroke mouse can be promoted, and the behavioral performance of the anxious mouse after the stroke can be relieved. The results show that the NAAA knockout or the NAAA inhibitor has obvious prevention and treatment effects on cerebral apoplexy and post-stroke anxiety related diseases, and has important significance on development of drugs for preventing and treating cerebral apoplexy and post-stroke anxiety in the future.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention specifically relates to the application of NAAA (i.e. N-acylethanolamine acid hydrolase) in preventing or treating stroke and post-stroke anxiety, and belongs to the technical field of biomedicine. Background Art

[0002] Stroke is caused by cerebral vascular stenosis, embolism or hemorrhage, which leads to reduced, interrupted or overflow of blood supply to the brain, causing brain tissue damage or dysfunction. Stroke has become the second leading cause of death in the world, and the incidence is showing a trend of younger people. Stroke can cause a series of adverse events such as mitochondrial failure and accumulation of reactive oxygen species, leading to a large number of neuronal damage. At present, the effective treatment for ischemic stroke is to use thrombolytics within a strict time window (4.5h) or to take surgical procedures to remove blood clots in time. However, most survivors still have a variety of sequelae, including physical dysfunction, cognitive impairment, negative emotions, etc. Post-stroke anxiety is one of the common and serious sequelae of stroke. About 21% of stroke patients will experience moderate to severe anxiety during the recovery period, including excessive tension, fear, and irritability, which not only affects the patient's daily life, but also imposes a heavy burden on the family and society. Therefore, it is particularly important to study the pathological mechanisms of stroke and post-stroke anxiety-related diseases and provide corresponding treatment strategies.

[0003] N-Acylethanolamine Acid Amidase (NAAA) is a cysteine ​​hydrolase that is mainly distributed in the lysosomes of immune cells and can specifically degrade endogenous lipid palmitoylethanolamide (PEA). PEA has multiple functions such as regulating pain, protecting nerves, and relieving inflammation. Therefore, the activity and expression level of NAAA directly affect the content and biological function of PEA in the brain. However, it is not clear whether NAAA is involved in the occurrence of stroke and post-stroke anxiety and the role of NAAA in this process. Summary of the invention

[0004] The main purpose of the present invention is to provide the use of NAAA as a target in the prevention or treatment of stroke and / or post-stroke anxiety, so as to overcome the deficiencies of the prior art.

[0005] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0006] The present invention provides the use of NAAA in preventing or treating stroke and / or post-stroke anxiety.

[0007] The present invention also provides the use of NAAA or a regulator of its encoding gene in the preparation of a drug for preventing or treating cerebral stroke and / or post-stroke anxiety.

[0008] The present invention also provides the use of NAAA or a regulator of its encoding gene in the preparation of a reagent for preventing or treating cerebral stroke and / or post-stroke anxiety.

[0009] The regulator is selected from small molecule compounds that specifically inhibit NAAA or its encoding gene.

[0010] In one embodiment, the modulator is selected from NAAA inhibitors, but is not limited thereto.

[0011] In one embodiment, the inhibitor is ARN077.

[0012] The present invention also provides the use of NAAA knockout in drugs for preventing or treating stroke and / or post-stroke anxiety.

[0013] The present invention also provides the use of NAAA knockout in preventing or treating stroke and / or post-stroke anxiety.

[0014] The present invention also provides the use of a substance with NAAA knocked out in the preparation of a drug for preventing or treating cerebral stroke and / or post-stroke anxiety.

[0015] The present invention also provides the use of a substance with NAAA knocked out in preparing a reagent for preventing or treating cerebral stroke and / or post-stroke anxiety.

[0016] The present invention also provides a pharmaceutical composition for preventing or treating stroke and / or post-stroke anxiety, which comprises a regulator of NAAA or its encoding gene, and a pharmaceutically acceptable carrier.

[0017] In one aspect, the present invention provides use of a pharmaceutical preparation containing a NAAA inhibitor in the preparation of a drug for preventing or treating stroke and post-stroke anxiety.

[0018] In one embodiment, the types of the pharmaceutical preparation include liquid dosage forms, solid dosage forms, semisolid dosage forms, and gas dosage forms.

[0019] In one embodiment, the liquid dosage form includes solutions, injections, etc.; the solid dosage form includes tablets, capsules, powders, granules, pills, etc.; the semi-solid dosage form includes ointments, eye ointments, gels, etc., and the gaseous dosage form includes aerosols, sprays, etc.

[0020] In one embodiment, the modulator is selected from small molecule compounds that specifically inhibit NAAA or its encoding gene.

[0021] In one embodiment, the modulator is selected from NAAA inhibitors, but is not limited thereto.

[0022] In one embodiment, the inhibitor is ARN077.

[0023] Compared with the prior art, the beneficial effect of the present invention is that the present invention proposes for the first time that NAAA is a drug target for treating stroke and / or post-stroke anxiety-related diseases. Experiments have shown that the expression of NAAA in the cerebral cortex is significantly increased in stroke (PTS) and post-stroke anxiety (PSA) mice. After a stroke, the infarct volume of NAAA knockout mice PTS 5 days later was significantly reduced, and the anxiety-like behaviors of NAAA knockout mice PSA 14 days, 16 days, and 18 days later in the buried beads, open field, and elevated cross maze experiments were significantly reduced. Continuous intraperitoneal injection of NAAA inhibitors for 3 days after a stroke can promote the recovery of the infarct area of ​​stroke mice and alleviate the behavioral manifestations of post-stroke anxiety mice. These results show that NAAA knockout or NAAA inhibitors have significant preventive and therapeutic effects on stroke and / or post-stroke anxiety-related diseases, which is of great significance for the future development of drugs for the prevention and treatment of stroke and / or post-stroke anxiety. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 A-1B is a graph showing the expression level of NAAA in the cortex of stroke and post-stroke anxiety mice in a typical embodiment of the present invention.

[0026] Figure 2 A-2B is a representative image and ischemic volume percentage diagram of brain magnetic resonance imaging of NAAA knockout mice after stroke in a typical embodiment of the present invention.

[0027] Figure 3 A-3B is a representative picture and a statistical graph of the number of buried beads in a bead burying experiment of NAAA knockout mice after stroke anxiety in a typical embodiment of the present invention.

[0028] Figure 3 C-3E is a representative picture of NAAA knockout mice after stroke anxiety in an open field test and a graph showing the moving distance and the percentage of time spent in the center in a typical embodiment of the present invention.

[0029] Figure 3 F-3G is a representative picture of NAAA knockout mice after stroke anxiety in an elevated plus maze test and a graph showing the percentage of time spent in the open arms in a typical embodiment of the present invention.

[0030] Figure 4A is a diagram showing the percentage of ischemic volume in brain magnetic resonance imaging after intraperitoneal injection of the NAAA inhibitor ARN077 in stroke mice in a typical embodiment of the present invention.

[0031] Figure 4 B is a statistical graph of the number of buried beads in a bead burying experiment after intraperitoneal injection of NAAA inhibitor ARN077 in post-stroke anxious mice in a typical embodiment of the present invention.

[0032] Figure 4 C-4D is a graph showing the moving distance and the percentage of time spent in the center in an open field test after intraperitoneal injection of the NAAA inhibitor ARN077 in stroke mice in a typical embodiment of the present invention.

[0033] Figure 4 E is a graph showing the percentage of time spent in the open arms in an elevated plus maze test in anxious mice after stroke after intraperitoneal injection of the NAAA inhibitor ARN077 in a typical embodiment of the present invention. DETAILED DESCRIPTION

[0034] In view of the defects of the prior art, the inventor of this case has proposed the technical solution of the present invention after long-term research and extensive practice. The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] Unless otherwise specified, the experimental materials used in the examples can be purchased from conventional biochemical reagent companies.

[0036] Unless otherwise specified, the materials and reagents used in the experiments can be obtained from commercial sources.

[0037] The relevant experimental results and analysis of this embodiment are as follows:

[0038] 1. Experimental steps

[0039] Experimental Animals:

[0040] The C57BL / 6J mice used in this example were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. - / -) Mice were purchased from Guangzhou Saiye Biotechnology Co., Ltd. Both types of mice were six-week-old male mice, randomly divided into groups, five per cage, with free access to food and water, and housed in a constant temperature and humidity animal room without specific pathogens. All experiments minimized the pain and discomfort of the animals as much as possible. All experiments strictly complied with the regulations of the Animal Use and Management Committee of the University of Science and Technology of China and were approved by the Ethics Committee of the Experimental Animal Center of the First Affiliated Hospital of the University of Science and Technology of China (Animal Ethics Approval No.: 2024-N(A)-175).

[0041] Reagents: ARN077 was purchased from MCE (MedChemExpress, Cas No. 1373625-34-3), DMSO was purchased from Aladdin (Cas No. 67-68-5), and Rose Bengal was purchased from MilliporeSigma (Cas No. 632-69-9).

[0042] Experimental Example 1: Establishment of the post-stroke anxiety model (PSA) and the post-stroke anxiety model (PTS)

[0043] After the mice were anesthetized with 3% isoflurane, the head was shaved and disinfected with iodine. The mice were fixed on a stereotaxic apparatus (Rayward, Shenzhen, China), and saline was dripped into the eyes of the mice to keep them moist. The skin of the head was lifted and cut along the midline to expose the skull on the right side of the brain, and then the connective tissue on the skull surface was cleaned. After leveling (the height difference between the anterior and posterior fontanelles was ≤±0.05mm, and the height difference between the left and right symmetrical parts was ≤±0.05mm), a skull drill was used to grind the right side of the mouse skull (AP, -0.3~-2.3mm; ML, 0.5~3.0mm) into a transparent area with a diameter of about 2mm, and the dura mater must not be damaged. A single intraperitoneal injection of rose solution (100mg / kg) was given, and after waiting for 5 minutes, a halogen light source was used to irradiate the exposed area for 10 minutes. The scalp incision was sutured with 5-0 thread, and postoperative resuscitation was performed on a heating pad. After full awakening, the mice were returned to the animal room for continued feeding. On the 1st to 3rd day after surgery, a bead burying behavior experiment was performed once a day to screen mice with post-stroke anxiety phenotype.

[0044] Experimental Example 2: MRI of Mouse Brain

[0045] Mice were anesthetized by 3% isoflurane induction and 1.5% isoflurane maintenance. The animal magnetic resonance system uMR 9.4T (United Imaging Medical) was used for the experiment. The respiratory rate and heart rate were continuously monitored during the scanning process. The T2-weighted fast spin echo (FSE) sequence parameters were set as follows: TR = 3000ms, TE = 49ms, ETL = 19, BW = 300Hz / pixel, FOV = 18×20mm 2, matrix size = 331 × 368, slice thickness = 0.5 mm, slice gap = 0 mm, scan 20 slices, average times = 4, total acquisition time = 15 minutes.

[0046] Experimental Example 3: Bead Burying Behavior Experiment

[0047] The bead burying experiment used a standard mouse cage (40cm×25cm×15cm), with about 5 cm thick odorless corn cob particles on the bottom. 15 black glass beads were evenly distributed on the bedding (3 beads / row, 5 rows in total, 4 cm spacing, and 15 mm in diameter). The mice were transferred to the behavioral room for adaptive training three days in advance. On the test day, each mouse was gently placed in the cage and allowed to explore freely for 30 minutes. The number of glass beads buried by the mouse in the bedding (covering more than two-thirds) was recorded. At the end of the experiment, the mice were returned to the breeding cage, and the experimental cage and glass beads were cleaned.

[0048] Experimental Example 4: Open Field Behavioral Experiment

[0049] The open field experiment consisted of a 50×50×50cm 3 The open field consists of a hollow, uncovered cube. Three days in advance, the mice were transferred to the behavioral room for adaptive training. On the test day, each mouse was gently placed in the center area of ​​the open field (25×25 cm) and allowed to explore freely for 5 minutes. The activity process was recorded using an overhead camera, and then the total distance the mice moved and the time they stayed in the center area were tracked and analyzed using Ethovision XT 14 (Noldus, the Netherlands) software. At the end of the experiment, the open field was wiped with 75% alcohol and clean water, respectively, to avoid odor interference.

[0050] Experimental Example 5: Elevated plus maze behavioral experiment

[0051] The elevated plus maze consists of two closed arms (35×5×10 cm 3 ) and two open arms (35×5×0.5cm 3 ) through a central platform (5×5×0.5cm 3 ) connection, 60 cm above the ground. The head and upper body of the mouse were randomly placed on the central platform, facing an open arm. Free exploration for 5 minutes. The activity process was recorded using an overhead camera, and then the time the mouse stayed in the open arm was tracked and analyzed using Ethovision XT 14 (Noldus, the Netherlands) software. At the end of the experiment, the elevated plus maze was wiped with 75% alcohol and clean water respectively to avoid odor interference.

[0052] Experimental Example 6: Intraperitoneal injection of NAAA inhibitor ARN077

[0053] ARN077 (MedChemExpress, Cas No. 1373625-34-3) was dissolved in physiological saline containing 0.1% DMSO (Aladdin, Cas No. 67-68-5). ARN077 (3 mg / kg) was intraperitoneally injected into mice for 3 consecutive days after PTS modeling.

[0054] Data analysis

[0055] All values ​​are expressed as mean ± standard error (SEM). Data were statistically analyzed using one-way ANOVA. *P≤0.05, **P≤0.01, ***P≤0.001.

[0056] All experiments were repeated 3 times or more, and the experimental results are expressed as mean ± standard error (SEM). The data were analyzed and plotted using GraphPad Prism 9.0 software. Student's T test was used for comparison between two groups, and one-way ANOVA combined with Bonferroni multiple test was used to determine the differences between multiple groups. * indicates P < 0.05, ** indicates P < 0.01, and *** indicates P < 0.001

[0057] 2. Experimental Results

[0058] 1. NAAA expression is increased in the cortex of stroke and post-stroke anxious mice

[0059] Male C57BL / 6J mice were divided into three groups: sham operation group (Sham group), stroke model group (PTS group), and post-stroke anxiety group (PSA group). After the mice were euthanized by cervical dislocation, the ischemic penumbra was taken for protein extraction, and NAAA was quantitatively analyzed by Western Blot. In stroke and post-stroke anxiety mice, the expression of NAAA was significantly increased. ( Figure 1 A-1B)

[0060] 2. NAAA knockout can promote the recovery of infarct area in stroke mice

[0061] Male C57BL / 6J and NAAA KO mice were divided into three groups: sham operation group (Sham group), stroke model group (WtPTS group), NAAA KO stroke model group (NAAA - / - PTS group). MRI imaging was performed on the 5th day after PTS modeling. Compared with the Wt PTS group, NAAA - / - The cerebral infarction volume in the PTS group was reduced. These results indicate that NAAA knockout can promote the recovery of infarction area in stroke mice. Figure 2 A-2B)

[0062] 3. NAAA knockout can alleviate behavioral manifestations of post-stroke anxiety in mice

[0063] Male C57BL / 6J and NAAA KO mice were divided into three groups: sham operation group (Sham group), post-stroke anxiety model group (Wt PSA group), NAAAKO post-stroke anxiety model group (NAAA - / - PSA group). On the 14th, 16th, and 18th days after modeling, mice were tested in the buried beads, open field, and elevated plus maze tests, respectively. Compared with the Wt PSA group, NAAA - / - The anxiety-like behaviors in the PSA group were significantly reduced. These results indicate that NAAA knockout can alleviate the behavioral manifestations of post-stroke anxiety mice. Figure 3 A-3G)

[0064] 4. NAAA inhibitors can promote the recovery of infarcted areas in stroke mice

[0065] Male C57BL / 6J mice were divided into three groups: sham operation group (Sham group), stroke model group (PTS+Veh group), stroke model and intraperitoneal injection of NAAA inhibitor ARN077 group (PTS+ARN077 group). MRI imaging was performed on the 5th day after PTS modeling. Compared with the PTS+Veh group, the cerebral infarction volume in the PTS+ARN077 group was reduced. These results indicate that intraperitoneal injection of NAAA inhibitor ARN077 group can promote the recovery of infarction area in stroke mice. ( Figure 4 A)

[0066] 5. NAAA inhibitors can alleviate behavioral manifestations of post-stroke anxiety in mice

[0067] Male C57BL / 6J mice were divided into three groups: sham operation group (Sham group), post-stroke anxiety model group (PSA+Veh group), post-stroke anxiety model and intraperitoneal injection of NAAA inhibitor ARN077 group (PSA+ARN077 group). On the 14th, 16th, and 18th days after modeling, mice were tested in buried beads, open field, and elevated plus maze experiments. Compared with the PSA+Veh group, the anxiety-like behavior of the PSA+ARN077 group was significantly reduced. These results indicate that intraperitoneal injection of the NAAA inhibitor ARN077 group can alleviate the behavioral manifestations of post-stroke anxiety mice. ( Figure 4 B-4E)

[0068] It should be understood that the technical solution of the present invention is not limited to the above-mentioned specific implementation cases. Any technical deformation made according to the technical solution of the present invention without departing from the scope of protection of the purpose of the present invention and the claims shall fall within the protection scope of the present invention.

Claims

1. Application of NAAA in the prevention or treatment of stroke and post-stroke anxiety.

2. Use of NAAA or a regulator of its encoding gene in the preparation of a drug or reagent for preventing or treating stroke and / or post-stroke anxiety.

3. Use of NAAA inhibitors in the preparation of drugs or reagents for preventing or treating stroke and / or post-stroke anxiety.

4. Use of a pharmaceutical composition containing a NAAA inhibitor in the preparation of a drug for preventing or treating stroke and post-stroke anxiety.

5. The use according to claim 4, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

6. Use of pharmaceutical preparations containing NAAA inhibitors in the preparation of drugs for preventing or treating stroke and post-stroke anxiety.

7. The use according to claim 6, wherein the types of the pharmaceutical preparation include liquid dosage forms, solid dosage forms, semisolid dosage forms, and gaseous dosage forms.

8. The use according to any one of claims 3 to 7, characterized in that: The NAAA inhibitor is ARN077.

9. Application of NAAA knockout in the prevention or treatment of stroke and / or post-stroke anxiety.

10. Use of a substance with NAAA knockout in the preparation of a drug or reagent for preventing or treating stroke and / or post-stroke anxiety.

Citation Information

Patent Citations

  • Composition containing ultra-micronized palmitoyl - ethanolamide

    CN102186459A

  • Carbamyl uracil derivative and application thereof

    CN105503741A

  • Wehonor strains as oral therapy for neuritis diseases

    CN116249540A

  • Palmitoylethanolamide compounds

    WO2021195555A1